Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Genedrive ( (GB:GDR) ) has provided an announcement.
Genedrive plc announced the implementation of its Genedrive® CYP2C19-ID Kit at Peterborough City Hospital’s Acute Stroke Centre for routine clinical use. This move is part of the company’s strategy to enhance its position in emergency care by providing rapid pharmacogenetic testing, which allows for personalized treatment plans for stroke patients. The implementation aims to optimize antiplatelet drug prescriptions, potentially improving patient outcomes and offering resource savings for healthcare systems. The company’s technology is expected to expand further within the UK NHS and internationally, contributing to better clinical management of stroke patients.
More about Genedrive
Genedrive plc is a UK-based pharmacogenetic testing company specializing in the development and commercialization of low-cost, rapid point-of-care platforms for diagnosing genetic variants. Their products, such as the Genedrive® MT-RNR1 ID Kit and the Genedrive® CYP2C19 ID Kit, are designed to aid clinicians in making informed decisions on medication and dosage, particularly in emergency healthcare settings. The company focuses on accelerating growth through in-market sales, geographic and portfolio expansion, and strategic mergers and acquisitions.
YTD Price Performance: -18.37%
Average Trading Volume: 3,191,562
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: £10.73M
For an in-depth examination of GDR stock, go to TipRanks’ Stock Analysis page.